HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas

Gut

Volumn 62, Issue 3, 2013, Pages 440-451

  Xiao, Qianyi ^a   Qu, Kai ^a   Wang, Chenji ^a   Kong, Yahui ^a   Liu, Chao ^a   Jiang, Deke ^a   Saiyin, Hexige ^a   Jia, Fan ^b   Ni, Canrong ^c   Chen, Taoyang ^d   Zhang, Yuanyuan ^a   Zhang, Pingzhao ^a   Qin, Wenxin ^e   Sun, Qingwen ^a   Wang, Hongyang ^f   Yi, Qing ^g   Liu, Jun ^h   Huang, Haojie ⁱ   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d Qi Dong Liver Cancer Institute   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF TEXAS   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; HEPATOMA DERIVED GROWTH FACTOR RELATED PROTEIN 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ANOIKIS; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANOIKIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, NUDE; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 84873407701     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300781     Document Type: Article

References (36)

1. Okuda K. Hepatocellular carcinomadrecent progress. Hepatology 1992;15:948e63.
2. Harris CC. Hepatocellular carcinogenesis: recent advances and speculations. Cancer Cells 1990;2:146e8.
3. Izumoto Y, Kuroda T, Harada H, et al. Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem Biophysical Res Commun 1997;238:26e32.
4. Everett AD, Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets 2003;4:367e71.
5. Nakamura H, Kambe H, Egawa T, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clinica Chim Acta 1989;183:273e84.
6. Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factordits homology with high-mobility group-1 protein. J Biol Chem 1994;269:25143e9.
7. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatomaderived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001;276:37564e8.
8. Kishima Y, Yamamoto H, Izumoto Y, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002;277:10315e22.
9. Everett AD, Lobe DR, Matsumura ME, et al. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000;105:567e75.
10. Zhou ZW, Yamamoto Y, Sugai F, et al. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem 2004;279:27320e6.
11. Marubuchi S, Okuda T, Tagawa K, et al. Hepatoma-derived growth factor, a new trophic factor for motor neurons, is up-regulated in the spinal cord of PQBP-1 transgenic mice before onset of degeneration. J Neurochem 2006;99:70e83.
12. Yang J, Everett AD. Hepatoma derived growth factor (HDGF) functions as a transcriptional repressor. FASEB J 2004;18:A31.
13. Zhang J, Ren HN, Yuan P, et al. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006;66:18e23.
14. Uyama H, Tomita Y, Nakamura H, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006;12:6043e8.
15. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of hepatoma-derived growth factor is correlated watch lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006;12:117e22.
16. Bernard K, Litman E, Fitzpatrick JL, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63:6716e25.
17. Chang KC, Tai MH, Lin JW, et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 2007;121:1059e65.
18. Hu TH, Lin JW, Chen HH, et al. The expression and prognostic role of hepatomaderived growth factor in colorectal stromal tumors. Dis Colon Rectum 2009;52:319e26.
19. Hu TH, Huang CC, Liu LF, et al. Expression of hepatoma-derived growth factor in hepatocellular carcinomada novel prognostic factor. Cancer 2003;98:1444e56.
20. Yoshida K, Nakamura H, Okuda Y, et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 2003;18:1293e301.
21. Yoshida K, Tomita Y, Okuda Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006;13:159e67.
22. Kishima Y, Yoshida K, Enomoto H, et al. Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepato-Gastroenterology 2002;49:1639e44.
23. El-Tahir HM, Dietz F, Dringen R, et al. Expression of hepatoma-derived growth factor family members in the adult central nervous system. BMC Neurosci 2006;7:6.
24. El-Tahir HM, Abouzied MM, Gallitzendoerfer R, et al. Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons. J Biol Chem 2009;284:11637e51.
25. Abouzied MM, Baader SL, Dietz F, et al. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 2004;378:169e76.
26. Chen J, Yu L, Li D, et al. Human CRYL1 a novel enzyme-crystallin overexpressed in liver and kidney and downregulated in 58% of liver cancer tissues from 60 Chinese patients, and four new homologs from other mammalians. Gene 2003;302:103e13.
27. Liu S, Ma LJ, Huang WX, et al. Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma. Cell Mol Biol Lett 2006;11:230e41.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57e70.
29. Ikegame K, Yamamoto M, Kishima Y, et al. A new member of a hepatoma-derived growth factor gene family can translocate to the nucleus. Biochem Biophysical Res Commun 1999;266:81e7.
30. Kumar S, Park SH, Cieply B, et al. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 2011;31:4036e51.
31. Wang Y, Ma X, Yan S, et al. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res 2009;69:7302e10.
32. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378e90.
33. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099e109.
34. Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Science 2003;94:1034e41.
35. Shibe S, Joly D, Liu ZX, et al. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004;16:257e67.
36. Ou DL, Shen YC, Liang JD, et al. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 2009;15:5820e8.